| Dr Edwin Kim King, DO | |
|
3212 Sw 89th, Suite 100, Oklahoma City, OK 73159-7907 | |
| (405) 378-3300 | |
| (405) 378-3993 |
| Full Name | Dr Edwin Kim King |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 39 Years |
| Location | 3212 Sw 89th, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033180484 | NPI | - | NPPES |
| 100200420A | Medicaid | OK | |
| P00265485 | Other | OK | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2534 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Gentle Shepherd Home Health, Inc | Oklahoma city, OK | Home health agency |
| Community Hospital, Llc | Oklahoma city, OK | Hospital |
| O U Medical Center | Oklahoma city, OK | Hospital |
| Integris Southwest Medical Center | Oklahoma city, OK | Hospital |
| Norman Regional | Norman, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Physicians Group, Llc | 8325950603 | 105 |
News Archive
Summer is here and it's time to get away. But while you are making vacation plans, take a few minutes to think about what you might do if an unexpected medical emergency should occur, especially if you are traveling away from home.
Mitochondrial protein ALDH4A1 has been identified as an autoantigen implicated in atherosclerosis.
Even mildly premature infants (gestational ages of 33 weeks through 36 weeks) have an increased risk of medically attended respiratory syncytial virus infection, which is the leading cause of lower respiratory tract infection in infants and young children and can lead to pneumonia in babies, according to a Kaiser Permanente Division of Research study.
Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration has accepted Eisai's New Drug Application for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease, and for the treatment of symptomatic GERD.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
› Verified 3 days ago
| Entity Name | The Physicians Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487620381 PECOS PAC ID: 8325950603 Enrollment ID: O20031104000641 |
News Archive
Summer is here and it's time to get away. But while you are making vacation plans, take a few minutes to think about what you might do if an unexpected medical emergency should occur, especially if you are traveling away from home.
Mitochondrial protein ALDH4A1 has been identified as an autoantigen implicated in atherosclerosis.
Even mildly premature infants (gestational ages of 33 weeks through 36 weeks) have an increased risk of medically attended respiratory syncytial virus infection, which is the leading cause of lower respiratory tract infection in infants and young children and can lead to pneumonia in babies, according to a Kaiser Permanente Division of Research study.
Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration has accepted Eisai's New Drug Application for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease, and for the treatment of symptomatic GERD.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edwin Kim King, DO 3212 Sw 89th, Suite 100, Oklahoma City, OK 73159-7907 Ph: (405) 378-3300 | Dr Edwin Kim King, DO 3212 Sw 89th, Suite 100, Oklahoma City, OK 73159-7907 Ph: (405) 378-3300 |
News Archive
Summer is here and it's time to get away. But while you are making vacation plans, take a few minutes to think about what you might do if an unexpected medical emergency should occur, especially if you are traveling away from home.
Mitochondrial protein ALDH4A1 has been identified as an autoantigen implicated in atherosclerosis.
Even mildly premature infants (gestational ages of 33 weeks through 36 weeks) have an increased risk of medically attended respiratory syncytial virus infection, which is the leading cause of lower respiratory tract infection in infants and young children and can lead to pneumonia in babies, according to a Kaiser Permanente Division of Research study.
Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration has accepted Eisai's New Drug Application for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease, and for the treatment of symptomatic GERD.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
› Verified 3 days ago
Alyssa Penick, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 608 Nw 9th St Ste 1100, Oklahoma City, OK 73102 Phone: 405-231-3000 | |
Dr. Carl Patrick Griffin, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 3555 Nw 58th St, Suite 801, Oklahoma City, OK 73112 Phone: 405-840-7003 Fax: 405-840-8221 | |
Dewey C Scheid, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 Ne 10th St, Oklahoma City, OK 73104 Phone: 405-271-4311 Fax: 405-271-2797 | |
Dr. Johnaqa Saidi, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 9220 S Pennsylvania Ave Ste A, Oklahoma City, OK 73159 Phone: 405-691-4497 Fax: 405-692-8807 | |
Mrs. Lauren Cathleen Hopkins, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3500 Nw 56th St Ste 100, Oklahoma City, OK 73112 Phone: 405-951-2855 | |
Dr. Gurdeep Singh Grewal, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 Ne 10th St, Oklahoma City, OK 73104 Phone: 405-271-4311 | |
Dr. Cynthia M Brennan, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 9100 N May Ave, Oklahoma City, OK 73120 Phone: 405-840-4456 Fax: 405-840-4295 |